Search Results - "Le Caer, H."

Multicentre phase II study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study by Le Treut, J., Sault, M.C., Lena, H., Souquet, P.J., Vergnenegre, A., Le Caer, H., Berard, H., Boffa, S., Monnet, I., Damotte, D., Chouaid, C.

“…The optimal treatment of large-cell neuroendocrine carcinoma (LCNEC) of the lung remains unclear. Here, our primary objective was to assess the efficacy of…”
Get full text

Classic biphasic pulmonary blastoma: A case report and review of the literature by Le Caer, H., Teissier, E., Barriere, J.R., Venissac, N.

“…Pulmonary blastomas represent about 0.5% of primary pulmonary malignancies. The prognosis is poor. Standard treatment consists of surgical excision. There are…”
Get full text

Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial by Pujol, J.-L., Lavole, A., Quoix, E., Molinier, O., Souquet, P.-J., Barlesi, F., Le Caer, H., Moro-Sibilot, D., Fournel, P., Oster, J.P., Chatellain, P., Barre, P., Jeannin, G., Mourlanette, P., Derollez, M., Herman, D., Renault, A., Dayen, C., Lamy, P.J., Langlais, A., Morin, F., Zalcman, G., Westeel, V., Poudenx, M., Mazieres, J., Martinet, Y., Gury, J-P., Baize, N., Dumont, P., Vaylet, F., Foucher, P., Dauba, J., Tredaniel, J., Laize, H., Petit, L., Coëtmeur, D., Doubre, H., Pichon, E., Schneider, S., Goutorbe, F., Gervais, R., Zaegel, M., Dehette, S., Coudert, B., Duhamel, J-P., Dixmier, A., Thiberville, L., Deguiral, P., Monnot, H., Romand, P., Berard, H., Raspaud, C.

“…IFCT study administering 7.5 mg/kg Bevacizumab plus chemotherapy after chemotherapy induction did not improve outcomes in extensive SCLC patients. This…”
Get full text

Bevacizumab as first-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC) in patients aged over 65 years in France: Final results of the AVANTAGE study by Lionel, F., Perol, D., Souquet, P.-J., Le Caer, H., Dansin, E., Audigier Valette, C., Mouysset, J.-L., Uffredi, M.L., Ionescu-Goga, M., Veerabudun, K., Lelarge, Y., Fabre-Guillevin, E.

Get full text

Hypofractionad radiotherapy for elderly with head and neck cancer by Ortholan, C, Auperin, A, Mertens, C, Le Caer, H, Guigay, J

“…Thirty percent of patients with head and neck cancer are over 70 years. Radiotherapy approach in elderly is a challenge. On one hand, radiotherapy side…”
Get full text

The ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit by Mertens, C., Le Caer, H., Ortholan, C., Blot, E., Even, C., Rousselot, H., Peyrade, F., Sire, C., Cupissol, D., Pointreau, Y., Debourdeau, P., Rolland, F., Fayette, J., Capitain, O., Sun, X., Debbah, M., Schwob, D., Boulahssass, R., Aupérin, A., Guigay, J.

Get full text

Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14 by Auliac, J B, Bayle, S, Vergnenegre, A, Le Caer, H, Falchero, L, Gervais, R, Doubre, H, Vinas, F, Marin, B, Chouaid, C

“…Mutations in are rare oncogene mutations, found in 2% of non-small-cell lung cancers (nsclcs). Little information is available about the management of patients…”
Get full text

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study by Auliac, J.B, Chouaid, C, Greiller, L, Monnet, I, Le Caer, H, Falchero, L, Corre, R, Descourt, R, Bota, S, Berard, H, Schott, R, Bizieux, A, Fournel, P, Labrunie, A, Marin, B, Vergnenegre, A

“…Abstract Background Concomitant administration of erlotinib with standard chemotherapy does not appear to improve survival among patients with non-small-cell…”
Get full text

PO-147: The ELAN program: Customised treatment of SCCHN elderly patients according to geriatric assessment by Guigay (France), J, Ortholan, C, Le Caer, H, Renardoldrini, S, Sun, X, Mayache-badis, L, Geoffrois, L, Fayette, J, Even, C, Vansteene, D, Pointreau, Y, Schwob, D, Vintonenko, N, Michel, C, Bourhis, J, Auperin, A, Mertens, C

Get full text

PO-071: ELAN Program: Personalized treatment according to geriatric assessment in elderly patients with head & neck cancer by Ortholan, C, Le Caer, H, Mertens, C, Leysalle, A, Even, C, Renard-Oldrini, S, Alfonsi, M, Pointreau, Y, Auperin, A

Get full text

Corrigendum to “Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study” [Lung Cancer 85 (2014) 415–419] by Auliac, J.B, Chouaid, C, Greillier, L, Monnet, I, Le Caer, H, Falchero, L, Corre, R, Descourt, R, Bota, S, Berard, H, Schott, R, Bizieux, A, Fournel, P, Labrunie, A, Marin, B, Vergnenegre, A

Get full text

Experience of multidisciplinary assessment of elderly patients with cancer in a French general hospital during 1 year: A new model care study by Bouzereau, V, Le Caer, F, Guardiola, E, Scavennec, C, Barriere, J.R, Chaix, L, Le Caer, H

“…Abstract Objectives Our main aim was to describe and explore a multidisciplinary approach to the management of elderly patients with cancer, who constitute a…”
Get full text

Elderly head and neck cancer (elan) study: Personalized treatment according to geriatric assessment in patients age 70 or older: First (SCCHN) unsuitable for surgery by Le Caer, H, Guigay, J, Mertens, C, Ortholan, C, Blot, E, Tao, Y, Peyrade, F, Pointreau, Y, Auperin, A

Get full text

P69 Study ESOGIA-GFPC 08–02 – elderly selection on geriatric index assessment by Corre, R, Vergnenègre, A, Le Caer, H, Fournel, P

Get full text

PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients: An Economical Analysis of a prospective Phase 2 Study (GFPC 0505) by Chouaid, C, Le Caer, H, Corre, R, Crequit, J, Jullian, H, Falchero, L, Dujon, C, Vergnenegre, A

Get full text

Non small-cell lung cancer in elderly. Which management? by Le Caer, H

“…Geriatric oncology has become recognised as a discrete speciality. Although there is a strong evidence base for using chemotherapy in patients with advanced…”
Get more information

Impact of a comprehensive geriatric assessment on management strategies in elderly patients with advanced no small cell lung cancer (NSCLC): A polled analysis of two phase 2 prospective study of the GFPC group by Le Caer, H, Chouaid, C, Corre, R, Locher, C, Raynaud, C, Berard, H, Auliac, J.B, Crequit, J, Decroisette, C, Borget, I

Get full text

P66 A multicenter phase II randomized study of docetaxel/gemcitabine weekly followed by erlotinib after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced non small cell lung cancer (NSCLC) in fit elderly patients selected with a comprehensive geriatric assessment (CGA) (gfpc0504): preliminary results by Le Caer, H, Barlesi, F, Corre, R, Jullian, H, Balas, D, Chouaid, C

Get full text

Comprehensive geriatric assessment and complications after resection for lung cancer by Raynaud, C, Le Caer, H, Borget, I, Jullian, H, Locher, C, Chouaid, C

“…With the expanding elderly population comes an increasing prevalence of lung cancer. Surgery remains the mainstay of treatment for early-stage non-small cell…”
Get more information

Randomized multicentric phase II study of carboplatin /gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie) by THOMAS, P, ROBINET, G, KLEISBAUER, J. P, GOUVA, S, FOURNEL, P, LENA, H, LE CAER, H, PEROL, M, BERARD, H, BOMBARON, P, VERGNENEGRE, A

“…To evaluate the efficacy and safety of gemcitabine and carboplatin in the treatment of previously untreated patients with advanced non-small cell lung cancer…”
Get full text